Abstracts tagged "BAFF"

Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Lucy M. Carter¹, David A. Isenberg² and Michael R. Ehrenstein³, ¹University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…
Abstract Number: 722 • 2013 ACR/ARHP Annual Meeting
BAFF Promotes T Follicular Helper Cell Development and Germinal Center Generation In Mice
Song Guo Zheng¹, Maogeng Chen¹, Qiang Li² and William Stohl³, ¹Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA, ³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: BAFF (B cell activating factor belonging to the TNF family) promotes B cells maturation in germinal center. The generation of germinal center depends on…
Abstract Number: 511 • 2013 ACR/ARHP Annual Meeting
Salivary Gland Lymphocyte Pattern Associated With Response To Belimumab In Primary sjogren’ssyndrome: Results Of The Beliss Study
Raphaèle Seror¹, Thierry Lazure², Frederic Desmoulins³, Stephan Pavy⁴, Corinne Miceli-Richard⁵, Gabriel Baron⁶, Philippe Ravaud⁷ and Xavier Mariette⁸, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Pathology, INSERM U1012 - Université Paris XI, Le Kremlin Bicêtre, France, ³Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁴Rheumatology, Hopital Bicetre, Paris, France, ⁵Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ⁶Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁸Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: To address the change in labial salivary gland (LSG) inflammation after Belimumab (biological treatment inhibiting soluble BAFF/BLyS) therapy in pSS patients and identify predictor…
Abstract Number: 1438 • 2012 ACR/ARHP Annual Meeting
Development of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice in the Absence of Any Single BAFF Receptor
Chaim O. Jacob¹, Ning Yu¹, Shunhua Guo¹, Noam Jacob¹, William J. Quinn III², Michael P. Cancro², Beatrice Goilav³, Chaim Putterman⁴, Thi-Sau Migone⁵ and William Stohl¹, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, ³Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Human Genome Sciences, Rockville, MD
Background/Purpose: To determine the necessity for any individual BAFF receptor in the development of SLE. Methods: NZM 2328 wild-type (WT), NZM.Bcma-/-, NZM.Taci-/-, and NZM.Br3-/-mice were…
Abstract Number: 987 • 2012 ACR/ARHP Annual Meeting
Autoimmune Susceptibility Genes Are Regulators of Gene Expression Response to ER Stress
William E. Bernal¹, Michael P. Morley² and Vivian G. Cheung³, ¹Division of Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Pediatrics & Genetics, Howard Hughes Medical Institute, Chevy Chase, MD; University of Pennsylvania, Philadelphia, PA
Background/Purpose: Endoplasmic recticulum (ER) stress is caused by excessive demands on the protein-processing capacity of the ER; inefficiencies in response to ER stress lead to…
Abstract Number: 877 • 2012 ACR/ARHP Annual Meeting
Aberrant Expression of BAFF Receptor (BR3) in Peripheral Monocytes of Patients with Primary Sjögren’s Syndrome Impacts Abnormal Activation of BAFF Signaling Through IKK-Alphaand IKK-Beta
Keiko Yoshimoto¹, Maiko Tanaka², Masako Kojima², Hideko Ogata², Hideto Kameda¹, Katsuya Suzuki¹, Tohru Abe³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, ⁴Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: B cell activating factor belonging to the TNF superfamily (BAFF) regulates proliferation, differentiation and survival of B cells and plays a pivotal role in…
Abstract Number: L6 • 2012 ACR/ARHP Annual Meeting
Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Richard A. Furie¹, Morton A. Scheinberg², Gustavo Leon³, Edgar B. Ramiterre⁴, Matthew Thomas⁵, Renee S. Martin⁶ and Michelle Petri⁷, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ³Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁴Brokenshire Memorial Hospital, Davao City, Philippines, ⁵Health and Research Centre, Trivandrum, Kerala, India, ⁶Anthera Pharmaceuticals Inc, Hayward, CA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To evaluate the efficacy, safety, and tolerability of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of soluble- and membrane-bound B-cell activating factor (BAFF), in patients…
Abstract Number: 2555 • 2012 ACR/ARHP Annual Meeting
Results of the Beliss Study, the First Open Phase 2 Study of Belimumab in Primary Sjogren’s Syndrome
Xavier Mariette¹, Luca Quartuccio², Raphaèle Seror³, Sara Salvin⁴, Frederic Desmoulins¹, Martina Fabris⁵, Sara Villeneuve⁶, Philippe Ravaud⁷ and Salvatore De Vita², ¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ²Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ³Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁴Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, ⁵Institute of Clinical Pathology, Udine, Italy, ⁶Epidemiology departement, Hospital Hotel dieu, Paris, France, ⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France
Background/Purpose: The BAFF (or BLyS) cytokine plays a key role in pathogenesis of primary Sjogren’s syndrome (pSS). Belimumab, the first biological treatment inhibiting soluble BAFF,…
Abstract Number: 1785 • 2012 ACR/ARHP Annual Meeting
MiR-30* Family Negatively Regulates B-Cell Activating Factor (BAFF) Synthesis in Rheumatoid Synoviocytes
Ghada Alsaleh¹, Antoine Francois², Lucas Philippe¹, Jean Sibilia¹, Jacques-Eric Gottenberg¹, Philippe Georgel³ and Dominique Wachsmann¹, ¹Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ²Laboratory of Physiopathology of Arthritises, University of Strasbourg, Illkirch-Strasbourg, France, ³Université de Strasbourg, Laboratoire d'ImmunoGénétique Moléculaire Humaine, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA) resident cells of the joint, fibroblast-like synoviocytes (RA FLS) acquire an aggressive phenotype in response to extrinsic factors such as…
Abstract Number: 1758 • 2012 ACR/ARHP Annual Meeting
Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy
Elena Becerra¹, Inmaculada de la Torre², Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College London, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: B-cell-activating-factor (BAFF) coordinates differentiation of B cells into immunoglobulin secreting cells (ISC) by binding to 3 different receptors (BBRs), namely BAFF-R, transmembrane activator and…
Abstract Number: 1757 • 2012 ACR/ARHP Annual Meeting
B Cell Activating Factor Receptor Expression After Rituximab: Comparison of Patients with Rheumatoid Arthritis and Thrombotic Thrombocytopenic Purpura
Elena Becerra¹, Maria J. Leandro¹, Edward O. Heelas², John P. Westwood², Inmaculada de la Torre³, Marie A. Scully² and Geraldine Cambridge¹, ¹Rheumatology, Rheumatology, University College London, London, United Kingdom, ²Hematology, Hematology, University College London, London, United Kingdom, ³Rheumatology, Rheumatology, Gregorio Marañón Hospital, Madrid, Spain
Background/Purpose: B cell depletion therapy based on rituximab (RTX) is an effective therapy for Rheumatoid Arthritis (RA) and for Thrombotic Thrombocytopenic Purpura (TTP). Serum B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].